Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 Combined with Camrelizumab in Advanced Primary Hepatocellular Carcinoma
NCT06124001Phase 2Not yet recruiting
- Sponsor
- Virogin Biotech
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
Phase 2, open-label, single-arm trial of VG161 in hepatocellular carcinoma (HCC), sponsored by Virogin Biotech. Primary endpoints: Recommended Phase II Dose / Maximum Tolerated Dose, Incidence and number of Dose-Limiting Toxicities and 2 more. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
VG161
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06124001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124001.